Welcome to our dedicated page for XPAC Acquisition news (Ticker: XPAXU), a resource for investors and traders seeking the latest updates and insights on XPAC Acquisition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XPAC Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XPAC Acquisition's position in the market.
XPAC Acquisition Corp. priced its initial public offering of 20 million units at $10.00 each, beginning trading on Nasdaq under the ticker symbol 'XPAXU' on July 30, 2021. Each unit comprises one Class A ordinary share and one-third of a redeemable warrant, with whole warrants allowing purchase of one Class A share at $11.50. The company, sponsored by XPAC Sponsor LLC affiliated with XP Inc., aims to target businesses in Brazil across various sectors. Citigroup serves as the book-running manager, and the offering includes a 45-day option for the underwriter to purchase additional units.
